Indaptus Therapeutics Q3 profit beats estimates

Reuters

Nov 12

Indaptus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 profit beats estimates

Overview

Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss
Company raised $2.3 mln through at-the-market facility, strengthening balance sheet
Research and development expenses increased due to Phase 1 study costs

Outlook

Indaptus expects current cash to support operations into Q1 2026
Company is evaluating financing options to support its strategy
Indaptus pauses trial enrollment pending further efficacy evaluations

Result Drivers

BALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facility
R&D EXPENSES - Increase due to Phase 1 study costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Beat	-$2.98	-$4.17 (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Indaptus Therapeutics Inc is $25.00, about 89.1% above its November 11 closing price of $2.72

Press Release: ID:nGNXxXz2j

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582374542"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582374542\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582374542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582374542","market":"nz","top_or_hot":-1,"title":"Indaptus Therapeutics Q3 profit beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 profit beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss</p></li><li><p>Company raised $2.3 mln through at-the-market facility, strengthening balance sheet</p></li><li><p>Research and development expenses increased due to Phase 1 study costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Indaptus expects current cash to support operations into Q1 2026</p></li><li><p>Company is evaluating financing options to support its strategy</p></li><li><p>Indaptus pauses trial enrollment pending further efficacy evaluations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facility</p></li><li><p>R&amp;D EXPENSES - Increase due to Phase 1 study costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$2.98</p></td><td><p>-$4.17 (1 Analyst)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Indaptus Therapeutics Inc is $25.00, about 89.1% above its November 11 closing price of $2.72</p></li></ul><p>Press Release: <span>ID:nGNXxXz2j</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indaptus Therapeutics Q3 profit beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndaptus Therapeutics Q3 profit beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 profit beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss</p></li><li><p>Company raised $2.3 mln through at-the-market facility, strengthening balance sheet</p></li><li><p>Research and development expenses increased due to Phase 1 study costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Indaptus expects current cash to support operations into Q1 2026</p></li><li><p>Company is evaluating financing options to support its strategy</p></li><li><p>Indaptus pauses trial enrollment pending further efficacy evaluations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facility</p></li><li><p>R&amp;D EXPENSES - Increase due to Phase 1 study costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$2.98</p></td><td><p>-$4.17 (1 Analyst)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Indaptus Therapeutics Inc is $25.00, about 89.1% above its November 11 closing price of $2.72</p></li></ul><p>Press Release: <span>ID:nGNXxXz2j</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INDP","symbol_name":"Indaptus Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0HI:1","article_id":"2582374542","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582374542","pubTimestamp":1762954705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Indaptus Therapeutics Q3 profit beats estimatesOverviewIndaptus Q3 2025 EPS beats analyst expectations, improving from last year's lossCompany raised $2.3 mln through at-the-market facility, strengthe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INDP":"Indaptus Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Indaptus Therapeutics第三季度利润超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDP":0.9},"content_text":"Indaptus Therapeutics Q3 profit beats estimatesOverviewIndaptus Q3 2025 EPS beats analyst expectations, improving from last year's lossCompany raised $2.3 mln through at-the-market facility, strengthening balance sheetResearch and development expenses increased due to Phase 1 study costsOutlookIndaptus expects current cash to support operations into Q1 2026Company is evaluating financing options to support its strategyIndaptus pauses trial enrollment pending further efficacy evaluationsResult DriversBALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facilityR&D EXPENSES - Increase due to Phase 1 study costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSBeat-$2.98-$4.17 (1 Analyst)Analyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Indaptus Therapeutics Inc is $25.00, about 89.1% above its November 11 closing price of $2.72Press Release: ID:nGNXxXz2jFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}